medigraphic.com
ISSN 2221-2434 (Electronic)

2012, Number 1

<< Back Next >>

Finlay 2012; 2 (1)

Dogmas and Updates on the Use of Beta-blockers in Secondary Prevention. Second Part

Morales SA

Language: Spanish
References: 11
Page: 68-69
PDF size: 72.80 Kb.


ABSTRACT

Because of the risk of acute bronchospasm, betablockers have traditionally been avoided in chronic obstructive pulmonary disease. Nevertheless, there is evidence showing that beta blockers can bring benefits in terms of cardiovascular morbidity and mortality and in general in this context. Both ischemic heart disease and chronic obstructive pulmonary disease have etiological "links", clinical, "in laboratory" and prognosis. Therefore, the management of this last must be of interest for cardiovascular health professionals.


REFERENCES

  1. Morales Salinas A. Los betabloqueadores como primera opción del tratamiento en la hipertensión no complicada: ¿posible o no? Revista Finlay [revista en Internet]. 2011[citado: 7 de julio de 2011]; 1(1): [Aprox. 7 p]. Disponible en: http:// www.revfinlay.sld.cu/index.php/finlay/article/ view/27/54

  2. Morales Salinas A. Dogmas y actualidades del uso de los beta-bloqueadores en prevención secundaria. Primera parte. Revista Finlay [revista en Internet]. 2011[citado: 10 Dic 2011];1(2):[aprox. 6p.]. Disponible en: http://www.revfinlay.sld.cu/index.php/ finlay/article/view/47/83.

  3. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.

  4. Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates C. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(2):CD003566.

  5. Tamargo J, Waagstein F, Tendera M, Lechat P, Torp- Pedersen C, López-Sendón J. Documento de Consenso de Expertos sobre bloqueadores de los receptores B-adrenérgicos. Rev Esp Cardiol. 2005;58:65-90.

  6. Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Rev Esp Cardiol [revista en Internet]. 2008[citado: 10 Dic 2011];61(12):[aprox. 150p.]. Disponible en: http:// www.revespcardiol.org/sites/default/files/elsevier/ pdf/25/25v61n12a13129755pdf001.pdf.

  7. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16(1):9–13.

  8. Berger JS, Sanborn TA, Sherman W, Brown DL. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol. 2004;94(5):649-51.

  9. De Gennaro L, Brunetti ND, Cuculo A, Pellegrino PL, Izzo P, Roma F, et al. Increased Troponin Levels in Nonischemic Cardiac Conditions and Noncardiac Diseases. J Intervent Cardiol. 2008;21(2):129-39.

  10. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26 (18):1887-94.

  11. Gaztañaga L, Marchlinski FE, Betensky BP. Mecanismos de las arritmias cardiacas. Rev Esp Cardiol. 2012;65(2):174–185.




2020     |     www.medigraphic.com